Krsnaa Diagnostics enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,615————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
30.230.23.82.422.7
53453420416032.5
2,119————
5045042001579.8
₹653.35————
1,5151,5151,086970771
35.3%35.3%18.7%16.5%4.2%
0.25×————
2.60×————
9.70×————
17.42×————
Reference items — trailing FY values
815773717620487
218212190144122
12212110269.768.5
—14387.324.376.3
−76.2−76.2−39.3−170−65.1
—−82.1−44.4−172−66.3
—219127194141
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

KRSNAA₹497.95

Krsnaa Diagnostics Limited

· Pharma & Health
₹ CrorePeersSURAKSHAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,615 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,615.3
- Cash, Equiv & ST Investments22.72.43.830.230.2
+ Total Debt32.5159.8203.5534.3534.3
Enterprise Value————2,119.3
Net Debt (memo)9.8157.4199.7504.1504.1
EV per Share————653.35
Total Capital771.2969.61,086.31,514.71,514.7
Total Debt/Total Capital4.2116.4818.7435.2835.28
Total Debt/EV————0.25
EV/Sales————2.60
EV/EBITDA————9.70
EV/EBIT————17.42
Reference Items — Trailing FY Values
Sales487.1619.6717.2772.8815.3
EBITDA122.3144.2190.1211.9218.5
EBIT68.569.7101.8121.4121.7
Operating Cash Flow76.324.387.3143.1—
Free Cash Flow-65.1-169.5-39.3-76.2-76.2
FCFF (free cash flow to the firm)-66.3-171.9-44.4-82.1—
Capital Expenditure141.4193.9126.6219.3—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.